Patents Examined by Alexandra F Connors
  • Patent number: 11920159
    Abstract: A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: March 5, 2024
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Paul S. Frenette, Fumio Nakahara
  • Patent number: 11802272
    Abstract: Methods of, treatments using, and devices for restoring the regenerative capability for mesenchymal stem cells and isolating and expanding a small subpopulation of less defective mesenchymal stem cells from the bone marrow stromal cells of people with decreased quality and/or quantity of mesenchymal stem cells, such as elderly people.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 31, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Travis Block, Milos Marinkovic, Xiao-dong Chen
  • Patent number: 11773387
    Abstract: The present invention relates to a device and a method for inducing pluripotent cells using energy and, more specifically, has an effect of inducing new type pluripotent cells having pluripotent characteristics by applying energy such as ultrasonic waves, lasers or heat treatment to differentiated cells.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 3, 2023
    Assignee: STEMON Inc.
    Inventor: Soonhag Kim
  • Patent number: 11752175
    Abstract: This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.
    Type: Grant
    Filed: September 21, 2019
    Date of Patent: September 12, 2023
    Assignee: Cornell University
    Inventors: John T. G. Pena, James Murray Mitchell, Harmon Lawrence Remmel
  • Patent number: 11746329
    Abstract: This disclosure pertains to a non-living biological product. Particularly, exosomes derived from stem cells can help restore heart function. According to certain embodiments, a fluid-induced shear stress mechanical stimulation process of stem cells is used to augmented quantity and quality of exosomes produced from stem cells. These exosomes serve as a therapeutic agent for the regenerative repair of diseases, such as diseased heart tissues. Therefore, compositions comprising the exosomes derived from stem cells and methods of treating a degenerative disease by administering the exosomes isolated from stem cells are also provided.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: September 5, 2023
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Sharan Ramaswamy, Manuel Perez, Yih-Mei Lin
  • Patent number: 11672756
    Abstract: The present invention provides a temperature sensitive hydrogel composition including a nucleic acid and chitosan. Since the hydrogel has excellent biocompatibility and biostability, and simultaneously has sol-gel phase transition properties depending on temperature changes, the hydrogel is present in a sol state at room temperature and becomes a gel when the hydrogel is injected into the human body or applied on the surface of epithelial skin and the temperature increases. Thus, the temperature-sensitive hydrogel of the present invention can be directly injected into and applied on certain parts requiring treatment and the retention and attaching time of a drug is increased through gelation depending on the temperature so that drug efficacy is sufficiently exhibited. Therefore, it is expected that the temperature-sensitive hydrogel of the present invention can be utilized for various treatments.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: June 13, 2023
    Assignee: PHARMARESEARCH CO., LTD.
    Inventors: Ik Soo Kim, Han Gyu Kim, Cheol Am Hong, Su Yeon Lee
  • Patent number: 11591573
    Abstract: The invention provides methods of preparing a sample of viable diseased cells obtained from a human subject for clinical testing, wherein the methods inhibit anoikis and/or anoikis in the cells while maintaining the physiological functions and genomic composition of the cells when they were in vivo. In the methods of the invention, primary cells are cultured in media comprising at least one anoikis inhibitor, preferably at least one inhibitor of an intrinsic anoikis pathway and at least one inhibitor of an extrinsic anoikis pathway, under anti-anoikis atmospheric conditions, such as greater than 2% and less than 20% oxygen. Method combining multiple culturing conditions, including surface attachment under conditions that inhibit anoikis, are also provided. Compositions and kits for use in the methods of the invention are also provided.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: February 28, 2023
    Assignee: Celcuity Inc.
    Inventors: Lance Gavin Laing, Ben Rich, Abhijit Dandapat
  • Patent number: 11485953
    Abstract: The present disclosure provides for a cell stabilizing medium which comprises gelatin. The cell stabilizing medium help maintain cell viability, e.g., after thawing of a biological material post-cryopreservation.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: November 1, 2022
    Assignee: TRANSWELL BIOTECH CO., LTD.
    Inventors: Ya-Hsuan Chang, Cheng-Yi Lin, Chih-Yuan Chao
  • Patent number: 11413311
    Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: August 16, 2022
    Assignees: MAPI PHARMA LTD., STEM CELL MEDICINE LTD.
    Inventors: Ehud Marom, Nadav Bleich Kimelman, Frida Grynspan
  • Patent number: 11401510
    Abstract: Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: August 2, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Finn Joseph Hawkins, Darrell N. Kotton, Shingo Suzuki, Brian R. Davis, Cristina Barillà
  • Patent number: 11395863
    Abstract: A method is disclosed for modifying a sheet-shaped cell culture containing at least two types of cells. The method includes soaking the sheet-shaped cell culture in a low nutrient isotonic solution; and changing a content ratio of the at least two cell types constituting the sheet-shaped cell culture.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 26, 2022
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Kenji Oyama, Ryohei Takeuchi, Toshikazu Takeuchi
  • Patent number: 11371020
    Abstract: This disclosure relates to methods of generating pacemaker cells for use in therapeutic strategies that address a heart that beats abnormally. In certain embodiments, one mixes cells with an epithelial-to-mesenchymal transformation inhibitor in combination with a nucleic acid encoding a transcription factor such as a vector that encodes a transcription factor such as Tbx18 in operable combination with a eukaryotic promoter to produce pacemaker cells that are then transplanted into the heart.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: June 28, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Hee Cheol Cho
  • Patent number: 11359178
    Abstract: The present invention provides a method for producing parasympathetic neurons from neural crest cells or autonomic neural progenitor cells derived therefrom, comprising a step of culturing the neural crest cells or autonomic neural progenitor cells derived therefrom in the presence of a cAMP production promoter, a BDNF signaling pathway activator, a GDNF signaling pathway activator, an NGF signaling pathway activator, an NT-3 signaling pathway activator, vitamin C, a protein kinase C activator, and a retinoic acid receptor agonist.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: June 14, 2022
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Yuzo Takayama, Yasuyuki Kida
  • Patent number: 11293870
    Abstract: A vital stain for observation under multiphoton laser microscopy, the vital stain comprising one or more edible dye compounds.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 5, 2022
    Assignee: MIE UNIVERSITY
    Inventors: Akira Mizoguchi, Takeshi Fujiwara, Koji Tanaka, Shujie Wang, Kousyoku Sai, Kazushi Kimura
  • Patent number: 11241516
    Abstract: The present invention refers to a process for preparing a biomaterial scaffold said method comprising, (a) providing a hydrogel comprising a fibrin network and a polysaccharide network; (b) subjecting the hydrogel of step a) to a freeze-thawing process to physically crosslink the hydrogel; and (c) subjecting the physically cross-linked hydrogel obtained after conducting the step b), to a lyophilization. The invention also relates to the biomaterial scaffold obtainable by the process as defined above, as well said biomaterial scaffold for its use to partially or completely increase, restore or replace the functional activity of a diseased or damaged oral mucosa.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: February 8, 2022
    Assignee: HISTOCELL, S.L.
    Inventors: María Begoña Castro Feo, Amparo Baiget Orts